Farxiga

In the Primary Composite Endpoint in DAPA-CKD, Farxiga reached __%.  In EMPA- Kidney, Jardiance reached __ % in the Primary Composite Endpoint. Clinical trials are not equal and can not compare results.

In a post hoc endpoint of DAPA-CKD, Farxiga's All Cause Hospitalization was  __%.   Jardiance secondary endpoint of All Cause Hospitalization was __%

The Number Needed to Treat (NNT) for Farxiga in DAPA-CKD was 19.  What was the NNT for Jardiance in EMPA- Kidney?

In DAPA- CKD, there was a secondary endpoint of All Cause Mortality (ACM) , Farxiga reached statistical significance of 31%.

 

EMPA Kidney did not reach statistical significance in their secondary endpoint of ACM what percentage did Jardiance reach__%?

The number of patients in the study for DAPA-CKD was ____.  EMPA Kidney had 6609 in the study.

The Length of DAPA-CKD was___years and  EMPA Kidney study length was 2.0 years. 

In DAPA - CKD the UACR median was___.  EMPA Kidney the median UACR was 329.